Tom Rees

@TomRees_MedComm

Communications Director at Oxford PharmaGenesis. Views expressed are my own and do not represent my employer.

Hove, UK
Vrijeme pridruživanja: siječanj 2014.

Tweetovi

Blokirali ste korisnika/cu @TomRees_MedComm

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @TomRees_MedComm

  1. Prikvačeni tweet
    14. velj 2014.

    Clinical trial data: it’s publishing, Jim, but not as we know it |

    Poništi
  2. prije 3 sata

    Top 10 most downloaded open access articles from T&F in 2019. Some corkers in there - and especially interesting to see the disconnect between downloads and other !

    Poništi
  3. 1. velj

    The next challenge in open access: open access for data mining. Current repositories are often not easily machine readable. "Whose Text, Whose Mining, and to Whose Benefit?"

    Poništi
  4. proslijedio/la je Tweet
    31. sij

    I am forever European, and value my European friends and colleagues so much. Please remember the actions of my country don't reflect my views or those of many others!

    Poništi
  5. 31. sij
    Poništi
  6. proslijedio/la je Tweet
    30. sij

    index as an alternative to ! Yay or nay - only time will tell!

    Poništi
  7. 29. sij

    How long before blockchain makes preprint servers redundant? And possibly conventional publishing altogether!

    Poništi
  8. proslijedio/la je Tweet
    29. sij

    The latest from the ⁦⁩ podcast looks at books and . With thanks to ⁦

    Poništi
  9. proslijedio/la je Tweet
    28. sij

    Great discussions at so far, including how to involve patients throughout the entire medicine development life cycle, which we believe is key to successful

    Poništi
  10. 26. sij

    A robust peer review process appears to be an important factor in journal choice for many authors

    Poništi
  11. proslijedio/la je Tweet
    22. sij

    "These authors demonstrated that Twitter is by far the most widespread platform for open social media dissemination with around 21% of papers receiving at least one tweet."

    Poništi
  12. 25. sij
    Poništi
  13. 23. sij

    "Smart" citations have so much potential - great to see that they are being integrated in Europe PMC

    Poništi
  14. proslijedio/la je Tweet
    2. sij

    Want to be part of our award-winning team? Click here to find out how to join us in 2020:

    Poništi
  15. proslijedio/la je Tweet
    22. sij

    A second poster from Shire (now Takeda) investigating the rates of Shire publications following their open access mandate

    Poništi
  16. proslijedio/la je Tweet
    22. sij

    bringing together transparency themes of , and at Clinical Data Disclosure, Transparency & Plain Language Summaries conference

    Poništi
  17. proslijedio/la je Tweet
    22. sij
    Poništi
  18. proslijedio/la je Tweet
    22. sij

    Pharma on - good reach/impact but even better for final journal articles. Our and research presented by Susan Wieting at Thanks to (ggridges) and (ggpairs)

    Poništi
  19. 22. sij

    “For a long time the debates have have been around why open access is a good thing. By and large that is now accepted, and the discussion is centred around how we can make it work for everyone,”'

    Poništi
  20. proslijedio/la je Tweet
    21. sij

    Thanks to everyone who took part in the round table at . A participant shared that a journal had refused them permission to reuse a Figure for a satellite symposium because it disapproved of that use. Has anyone else seen a journal use CC BY NC in that way?

    Poništi
  21. 21. sij

    Sarah Sabir of presents on the incomplete (but growing) uptake of by at

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·